PAH patients get extended access to riociguat in safety study

NCT ID NCT02759419

Completed Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 20, 2026 · Updated 26 times

Summary

This study gave long-term riociguat (Adempas) to 18 adults with pulmonary arterial hypertension who had already taken the drug in earlier Bayer trials. The main goal was to check safety and side effects over time. Patients stayed on the drug until it was no longer helpful or became commercially available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION, PULMONARY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Study site

Besançon, 25030, France
Study site

Brest, F-29609, France
Study site

Le Kremlin-Bicêtre, 94275, France
Study site

Lille, 59037, France
Study site

Rouen, 76031, France
Study site

Seoul, Seoul Teugbyeolsi, 03722, South Korea
Study site

Seoul, Seoul Teugbyeolsi, 05505, South Korea
Study site

Seoul, Seoul Teugbyeolsi, 3080, South Korea
Study site

Seoul, 06351, South Korea

Conditions

Explore the condition pages connected to this study.

HYPERTENSION, PULMONARY